• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Fertility Pioneer and Kindbody Founder Gina Bartasi Returns as CEO to Lead Company's Next Phase of Growth

    6/11/24 11:00:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email

    Kindbody is the Largest Women-founded, Women-led Fertility Company Serving Employers and Families through its National Clinic Network and Proprietary Technology Platform

    NEW YORK, June 11, 2024 /PRNewswire/ -- Kindbody, the leading national fertility clinic network and global family-building benefits provider for employers, today announced its Founder and Executive Chairman, Gina Bartasi, will return as the company's CEO during a time of unprecedented growth. The Company recently shared that it expected to deliver revenue in the range of $225-$250 million for 2024 and is now profitable after years of significant investment into new clinic locations and proprietary technology. Bartasi succeeds Annbeth Eschbach after months of succession planning, partnering to ensure the team and business continues on its remarkable growth and profitability. Eschbach will continue her support as an Operating Partner in the coming months. Kindbody also announced that Gina Bruzzichesi, who joined the Company earlier this year as Chief Operating Officer, has been promoted to President, and Haleigh Tebben, has been promoted from Chief Revenue Officer to Chief Commercial Officer.

    Gina Bartasi, Kindbody Founder and CEO

    Bartasi founded Kindbody in late 2018 and opened its first flagship location in Manhattan in September 2019 to forever change the face of family-building care, making it more equitable and affordable. Bartasi is a well-respected leader in the fertility industry having founded Progyny (NASDAQ:PGNY) and FertilityAuthority. Bartasi subsequently founded Kindbody to serve the demand from large, self-insured employers to purchase fertility benefits directly from providers circumventing the intermediary and saving millions.

    Kindbody is the largest women-founded, women-led fertility company providing family-building and women's healthcare benefits to 121 employers covering more than 3.1M lives. The company provides women's healthcare from menarche to menopause both virtually and in-clinic. It saves employers 25%-30% through direct contracting, and currently services all 50 states and 108 countries outside the U.S. through a network of 35 owned and operated signature clinics. Kindbody's model is highly differentiated in that it is the only family-building benefits provider for employers that owns and operates fertility clinics. As the direct provider of care, Kindbody is uniquely positioned to decrease cost, improve the patient experience, and deliver better health outcomes.

    "I'm incredibly proud of our world class team and the hard work and enthusiasm they've shown to build something industry leading and game changing. There's more work to do and we're eager to continue to lead the way. Our team and their dedication is inspiring to any leader who wants to do more, so I'm honored to return," said Kindbody's Founder and Chair and incoming CEO Gina Bartasi. "Our mission, since inception, has been to prioritize patient care by reducing the friction and fragmentation in healthcare. In the last several years, we've launched Kindlabs, our in-house PGT-A business, Kind360, our holistic women's healthcare services treating mental healthcare and nutrition, KindEOS, our embryo, oocyte and surrogacy agency, KindRx, Kinddoula and Kindbaby".

    As President, Gina Bruzzichesi will oversee the company's day-to-day operations, ensuring operational, people, and technology excellence, and driving the execution of strategic initiatives. Bruzzichesi joined Kindbody earlier this year and has deep leadership experience in human resources and operations, having run a $2 billion division at Aspen Dental Management, where she served as Chief Operating Officer, as well as at CLEAR, WeWork, and Avis. Additionally, the company is promoting Haleigh Tebben from Chief Revenue to Chief Commercial Officer. In this new role, Tebben will oversee employer revenue and marketing. Tebben has 25 years of experience in insurance, consulting, and healthcare, including serving as Chief Commercial Officer at Brightline.

    From its founding, Bartasi believed healthcare couldn't truly be changed without first investing in technology, so its initial seed capital acquired the foundational code for KindEMR. Fertility is highly predictable and the objective was to replace anecdotal decision-making with predictive technology.

    Kindbody's proprietary technology is centered on its HIPAA compliant electronic medical record (KindEMR) for increased standardization of care, offering online scheduling for virtual and in-person appointments and an intuitive patient portal.

    The KindEMR supports the full spectrum of reproductive health and family-building care including both female and male fertility, fertility preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. Additionally, Kindbody has invested heavily to improve artificial intelligence (AI) in fertility treatment. The Company is working on several AI products including: a more personalized, standardized decision making tool allowing for more efficiency for the provider; an improved prognosis tool so the patient knows what to expect and predicts their likelihood of success; and AI in the lab to better predict which embryo is best to transfer and which egg is best to fertilize.

    About Kindbody

    Kindbody is the leading national fertility clinic network and global family-building benefits provider for employers offering the full spectrum of reproductive care from preconception to postpartum through menopause. Kindbody is the trusted fertility benefits provider for 121 leading employers, covering 3.1 million lives. Many thousands more receive their fertility care directly from Kindbody throughout the country at signature clinics, mobile clinics, and partner clinics. As the fertility benefits provider, technology platform, and direct provider of care, Kindbody delivers a seamless, integrated experience with superior health outcomes at lower cost, making fertility care more affordable and accessible for all. Kindbody has raised $315 million in debt and equity funding from leading investors including Perceptive Advisors, JP Morgan Chase's Morgan Health, GV (formerly Google Ventures), RRE Ventures, Claritas Health Ventures, Rock Springs Capital, Walleye Capital, Bramalea, Monashee Capital, and Whatif Ventures. Visit www.kindbody.com. and follow us on Instagram, X, and Linkedin.

    Contact:

    Margaret Ryan

    Kindbody

    [email protected]

    Kindbody is the leading fertility clinic network and global family-building benefits provider for employers. (PRNewsfoto/Kindbody)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fertility-pioneer-and-kindbody-founder-gina-bartasi-returns-as-ceo-to-lead-companys-next-phase-of-growth-302168772.html

    SOURCE Kindbody

    Get the next $PGNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    1/20/2026$30.00Mkt Perform → Mkt Outperform
    Citizens JMP
    1/8/2026$34.00Hold → Buy
    Truist
    12/9/2025$29.00Overweight
    Barclays
    11/12/2025$30.00Sector Weight → Overweight
    KeyBanc Capital Markets
    7/8/2025$28.00Market Perform → Outperform
    Leerink Partners
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    9/19/2024Mkt Outperform → Mkt Perform
    JMP Securities
    More analyst ratings

    $PGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Clapp Geoffrey

    4 - Progyny, Inc. (0001551306) (Issuer)

    3/19/26 5:12:56 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    EVP, GC Swartz Allison covered exercise/tax liability with 339 shares and sold $10,506 worth of shares (599 units at $17.54), decreasing direct ownership by 1% to 88,941 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    3/6/26 4:36:37 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 339 shares, decreasing direct ownership by 0.39% to 87,338 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    3/6/26 4:35:02 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Progyny Commemorates 10 Years of Redefining Women's Health and Family Building Care

    NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Over the past ten years, millions of individuals and families have gained access to life-changing benefits through Progyny, a global leader in women's health and family building solutions. Progyny today announces that throughout the year, it will honor the collective efforts of its members, employers, providers, and industry partners who have helped shape this decade of progress. The company has redefined what's possible in the benefits industry by combining clinical expertise, innovation, and a personalized approach to support members at every stage, from preconception through menopause. "Ten years ago, we set out to transform family building

    4/1/26 9:23:11 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Executives to Participate in Upcoming Investor Conferences

    NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that several members of its leadership team will participate in upcoming investor conferences in March, including the Leerink Partners Global Healthcare Conference, the Barclays Global Healthcare Conference, and the KeyBanc Capital Markets Healthcare Forum. At the Leerink Partners Global Healthcare Conference, Mark Livingston, Chief Financial Officer, will participate in a fireside chat on March 10, 2026, at 10:40 a.m. Eastern Time. At the Barclays Global Healthcare Conference, Pete Anevski, Chief Executive Officer, will participate in

    3/6/26 9:02:47 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Fourth Quarter 2025 Results

    Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent AuthorizationIssues Financial Guidance for 2026, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three- and twelve-month periods ended December 31, 2025 ("the fourth quarter of 2025" and "the full year", resp

    2/26/26 4:01:00 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Progyny upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Progyny from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    1/20/26 8:45:21 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny upgraded by Truist with a new price target

    Truist upgraded Progyny from Hold to Buy and set a new price target of $34.00

    1/8/26 9:26:52 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Barclays initiated coverage on Progyny with a new price target

    Barclays initiated coverage of Progyny with a rating of Overweight and set a new price target of $29.00

    12/9/25 8:52:58 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Anevski Peter bought $1,930,896 worth of shares (79,500 units at $24.29), increasing direct ownership by 13% to 680,251 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    11/17/25 8:22:02 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Executive Chairman Schlanger David J bought $2,202,330 worth of shares (150,000 units at $14.68), increasing direct ownership by 192% to 228,269 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    12/26/24 5:35:03 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    CHIEF EXECUTIVE OFFICER Anevski Peter bought $3,034,084 worth of shares (209,500 units at $14.48), increasing direct ownership by 90% to 441,463 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    12/26/24 5:31:32 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    SEC Filings

    View All

    SEC Form PRE 14A filed by Progyny Inc.

    PRE 14A - Progyny, Inc. (0001551306) (Filer)

    3/31/26 4:33:46 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.

    SCHEDULE 13G/A - Progyny, Inc. (0001551306) (Subject)

    3/27/26 11:19:23 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Progyny, Inc. (0001551306) (Filer)

    3/13/26 4:15:27 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Leadership Updates

    Live Leadership Updates

    View All

    Progyny CEO Named World Economic Forum Champion for Women's Health

    NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that CEO Pete Anevski has been honored with the recognition as a Champion for Women's Health by the World Economic Forum (the Forum) and the Global Alliance for Women's Health (GAWH). The community of Champions is a distinguished group of global leaders who are playing a critical role in driving advocacy efforts, shaping policies, fostering innovation, and unlocking investments to advance women's health. The exclusive Champions community spans diverse sectors, industries, and geographies, and includes figures such as: Helen Clark, former

    10/7/25 9:30:50 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Appoints Two Renowned Women's Health Experts to Medical Advisory Board

    NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the appointment of Morehouse School of Medicine's Regional Dean for Seattle and Puget Sound's Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (MSCP) – and Columbia University's Dr. Whitney Booker – a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine – to its Medical Advisory Board. "As Pr

    5/14/25 9:05:48 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

    NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

    4/17/25 9:36:59 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Financials

    Live finance-specific insights

    View All

    Progyny, Inc. Announces Fourth Quarter 2025 Results

    Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent AuthorizationIssues Financial Guidance for 2026, Reflecting Tenth Consecutive Year of Revenue Growth NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three- and twelve-month periods ended December 31, 2025 ("the fourth quarter of 2025" and "the full year", resp

    2/26/26 4:01:00 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report

    NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period and full year ended December 31, 2025, after the close of the market on Thursday, February 26, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using t

    2/12/26 2:46:53 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Third Quarter 2025 Results

    Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and Near 100% Retention of Existing BaseRecord $156.0 Million in Operating Cash Flow Generated over the First Nine Months of 2025Board Authorizes Up to $200 Million in Share Repurchase Program NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended September 30, 2025 ("the third quarter of 2025"), as compared to the th

    11/6/25 4:01:00 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    12/6/24 10:11:35 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    11/14/24 4:31:23 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Progyny Inc. (Amendment)

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    2/14/24 6:29:49 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care